Sophia GeneticsFRA:90B +6.61%72 EBITDA Margin % is -67.55% as of Mar. 2026. GuruFocus rates FRA:90B with a GF Score™ of 72/100 and a GF Value™ of €4.27 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 668 Healthcare Providers & Services companies, Sophia Genetics ranks worse than 90.27% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Sophia Genetics's EBITDA for the
three
months ended in Mar. 2026 was €-12.67 Mil. Sophia Genetics's Revenue for the
three
months ended in Mar. 2026 was €18.76 Mil. Therefore, Sophia Genetics's EBITDA margin for the quarter that ended in Mar. 2026 was -67.55%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Sophia Genetics EBITDA Margin % Related Terms
Sophia Genetics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Sophia Genetics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:90B vs SLP, TBRG, CARL: EBITDA Margin % Comparison
For the Health Information Services subindustry, Sophia Genetics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sophia Genetics EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Sophia Genetics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Sophia Genetics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sophia Genetics (FRA:90B) has a EBITDA Margin % of -67.55% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sophia Genetics and its competitors. According to the industry distribution chart, Sophia Genetics ranks #603 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 90.3%.
Is Sophia Genetics' EBITDA Margin % too high?
Sophia Genetics' current EBITDA Margin % is -67.55%. Based on the distribution chart, Sophia Genetics ranks #603 out of 668 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Sophia Genetics has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sophia Genetics' EBITDA Margin % compare to SLP and TBRG?
According to the Healthcare Providers & Services industry distribution chart, Sophia Genetics ranks #603 out of 668 companies for EBITDA Margin %. This places Sophia Genetics in the lower half of its industry. The industry median EBITDA Margin % is 10.21. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sophia Genetics and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sophia Genetics's current EBITDA Margin % is -67.55%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sophia Genetics stock overvalued right now?
Based on GuruFocus' analysis, Sophia Genetics (FRA:90B) is currently considered Modestly Overvalued. The stock's GF Value™ is €4.27, compared to a current price of €4.84 — trading 13.3% above its estimated fair value. The current EBITDA Margin % is -67.55%. Sophia Genetics' overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Sophia Genetics (FRA:90B), the current EBITDA Margin % is -67.55% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sophia Genetics (FRA:90B) Overvalued in 2026?
Based on GuruFocus' analysis, Sophia Genetics stock appears to be overvalued.
The current stock price of €4.84 is trading 13.3% above its estimated GF Value™ of €4.27.
GuruFocus considers Sophia Genetics to be Modestly Overvalued.
Key valuation signals for FRA:90B:
EBITDA Margin %: -67.55%
GF Value™: €4.27 vs. price of €4.84 (13.3% above fair value)
No single metric tells the full story. See the FRA:90B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
72GF Score
Get the complete analysis for FRA:90B
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:90B has been successfully added to your 
